Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
transglutaminase 2 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal
01
Overview
Transglutaminase 2 siRNA (TGM2 siRNA) is a small interfering RNA designed to silence the expression of transglutaminase 2 (TGM2), a multifunctional enzyme involved in protein cross-linking, cell adhesion, and signal transduction. In preclinical research, TGM2 siRNA is utilized to investigate the role of TGM2 in various pathological conditions, including obesity-associated inflammation, celiac disease, and chemoresistance in cancers such as breast and ovarian cancer. By knocking down TGM2 expression, researchers can evaluate its impact on cellular processes like autophagy, apoptosis, and cytokine production.
- Other names
- TG2 siRNATG-2 siRNATG 2 siRNATGM2 siRNATGM-2 siRNATGM 2 siRNAtransglutaminase 2 small interfering RNAtransglutaminase2 small interfering RNAtransglutaminase-2 small interfering RNA
02
Targets
AGO2 (Argonaute RISC catalytic component 2)TGM2 (Tissue Transglutaminase 2)
Beyond the preview
Go deeper on transglutaminase 2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on transglutaminase 2 siRNA.